Literature DB >> 26500098

Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2.

Andrea Mancikova1, Vladimir Krylov1, Olha Hurba2, Ivan Sebesta2,3, Makiko Nakamura4, Kimiyoshi Ichida4,5, Blanka Stiburkova6,7.   

Abstract

BACKGROUND: Renal hypouricemia is a rare heterogeneous inherited disorder characterized by impaired tubular uric acid transport with severe complications, such as acute kidney injury and nephrolithiasis. Type 1 is caused by a loss-of-function mutation in the SLC22A12 gene (URAT1), while type 2 is caused by defects in the SLC2A9 gene (GLUT9). METHODS AND
RESULTS: In this article we present clinical, biochemical and molecular genetics of two Czech patients. The serum uric acid in the probands was 57 and 98 µmol/l and expressed as an increase in the fractional excretion of uric acid (40 and 18 %). The sequencing analysis of SLC22A12 and SLC2A9 revealed novel variants p.R92C and p.R203C in URAT1 and p.G72D in GLUT9. Functional studies were performed for these novel variants and for previously reported variants p.I118HfsX27, p.G216R and p.N333S in GLUT9 responsible for renal hypouricemia in three probands from Czech Republic and United Kingdom. Functional studies showed significantly decreased urate uptake for all variants. However, urate uptake of GLUT9 variants prepared for both isoforms were not significantly different.
CONCLUSIONS: This is the first complex function characterization of non-synonymous allelic variants in patients with renal hypouricemia regarding both GLUT9 isoforms. Our finding of defects in the SLC2A9 and SLC22A12 genes show the following: renal hypouricemia is not restricted to East Asia populations; urate uptake of GLUT9 variants prepared for both isoforms were not significantly different; renal hypouricemia type 2 has more wide clinical variability than type 1; the phenotypic severity of renal hypouricemia is not correlated with results of functional characterizations of URAT1 and GLUT9 variants.

Entities:  

Keywords:  GLUT9; Renal hypouricemia; SLC22A12; SLC2A9; URAT1; Uric acid transporters

Mesh:

Substances:

Year:  2015        PMID: 26500098     DOI: 10.1007/s10157-015-1186-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  27 in total

1.  High frequency of SLC22A12 variants causing renal hypouricemia 1 in the Czech and Slovak Roma population; simple and rapid detection method by allele-specific polymerase chain reaction.

Authors:  Dana Gabrikova; Jarmila Bernasovska; Jitka Sokolova; Blanka Stiburkova
Journal:  Urolithiasis       Date:  2015-06-02       Impact factor: 3.436

2.  Diagnostic tests for primary renal hypouricemia.

Authors:  Ivan Sebesta; Blanka Stiburkova; Josef Bartl; Kimiyoshi Ichida; Makoto Hosoyamada; Judy Taylor; Anthony Marinaki
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2011-12       Impact factor: 1.381

3.  Recurrent EIARF and PRES with severe renal hypouricemia by compound heterozygous SLC2A9 mutation.

Authors:  Yuko Shima; Kandai Nozu; Yoshimi Nozu; Hiroko Togawa; Hiroshi Kaito; Masafumi Matsuo; Kazumoto Iijima; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Pediatrics       Date:  2011-05-02       Impact factor: 7.124

4.  URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews.

Authors:  Dganit Dinour; Andrew Bahn; Liat Ganon; Rotem Ron; Ossie Geifman-Holtzman; Aaron Knecht; Uzi Gafter; Ruth Rachamimov; Ben-Ami Sela; Gerhard Burckhardt; Eliezer J Holtzman
Journal:  Nephrol Dial Transplant       Date:  2010-12-09       Impact factor: 5.992

5.  Genome-wide association of serum uric acid concentration: replication of sequence variants in an island population of the Adriatic coast of Croatia.

Authors:  Rebekah Karns; Ge Zhang; Guangyun Sun; Subba Rao Indugula; Hong Cheng; Dubravka Havas-Augustin; Natalija Novokmet; Dusko Rudan; Zijad Durakovic; Sasa Missoni; Ranajit Chakraborty; Pavao Rudan; Ranjan Deka
Journal:  Ann Hum Genet       Date:  2012-01-09       Impact factor: 1.670

6.  Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9).

Authors:  J E Phay; H B Hussain; J F Moley
Journal:  Genomics       Date:  2000-06-01       Impact factor: 5.736

7.  Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis.

Authors:  Blanka Stiburkova; Ivan Sebesta; Kimiyoshi Ichida; Makiko Nakamura; Helena Hulkova; Vladimir Krylov; Lenka Kryspinova; Helena Jahnova
Journal:  Eur J Hum Genet       Date:  2013-02-06       Impact factor: 4.246

8.  Homozygous SLC2A9 mutations cause severe renal hypouricemia.

Authors:  Dganit Dinour; Nicola K Gray; Susan Campbell; Xinhua Shu; Lindsay Sawyer; William Richardson; Gideon Rechavi; Ninette Amariglio; Liat Ganon; Ben-Ami Sela; Hilla Bahat; Michael Goldman; Joshua Weissgarten; Michael R Millar; Alan F Wright; Eliezer J Holtzman
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

9.  Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese.

Authors:  K Ichida; M Hosoyamada; N Kamatani; S Kamitsuji; I Hisatome; T Shibasaki; T Hosoya
Journal:  Clin Genet       Date:  2008-05-15       Impact factor: 4.438

10.  Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout.

Authors:  Olha Hurba; Andrea Mancikova; Vladimir Krylov; Marketa Pavlikova; Karel Pavelka; Blanka Stibůrková
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

View more
  15 in total

1.  Hypouricemia and hyperuricosuria in a pubescent girl: Answers.

Authors:  Blanka Stiburkova; Ivan Sebesta
Journal:  Pediatr Nephrol       Date:  2018-03-12       Impact factor: 3.714

Review 2.  Urate transport in health and disease.

Authors:  Victoria L Halperin Kuhns; Owen M Woodward
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-10-21       Impact factor: 4.098

Review 3.  The genetic framework for development of nephrolithiasis.

Authors:  Vinaya Vasudevan; Patrick Samson; Arthur D Smith; Zeph Okeke
Journal:  Asian J Urol       Date:  2016-11-28

4.  Phloretin attenuates hyperuricemia-induced endothelial dysfunction through co-inhibiting inflammation and GLUT9-mediated uric acid uptake.

Authors:  Shuyun Liu; Yujia Yuan; Yijie Zhou; Meng Zhao; Younan Chen; Jingqiu Cheng; Yanrong Lu; Jingping Liu
Journal:  J Cell Mol Med       Date:  2017-04-12       Impact factor: 5.310

Review 5.  Multiple Membrane Transporters and Some Immune Regulatory Genes are Major Genetic Factors to Gout.

Authors:  Weifeng Zhu; Yan Deng; Xiaodong Zhou
Journal:  Open Rheumatol J       Date:  2018-07-24

6.  A heterozygous variant in the SLC22A12 gene in a Sri Lanka family associated with mild renal hypouricemia.

Authors:  Dinesha Maduri Vidanapathirana; Subashinie Jayasena; Eresha Jasinge; Blanka Stiburkova
Journal:  BMC Pediatr       Date:  2018-06-29       Impact factor: 2.125

7.  Amplicon targeted resequencing for SLC2A9 and SLC22A12 identified novel mutations in hypouricemia subjects.

Authors:  Zhaowei Zhou; Ke Wang; Juan Zhou; Can Wang; Xinde Li; Lingling Cui; Lin Han; Zhen Liu; Wei Ren; Xuefeng Wang; Keke Zhang; Zhiqiang Li; Dun Pan; Changgui Li; Yongyong Shi
Journal:  Mol Genet Genomic Med       Date:  2019-05-26       Impact factor: 2.183

Review 8.  Urate Transporters in the Kidney: What Clinicians Need to Know.

Authors:  Sungjin Chung; Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2021-06-30

9.  An Intron Variant of SLC2A9 Increases the Risk for Type 2 Diabetes Mellitus Complicated with Hyperuricemia in Chinese Male Population.

Authors:  Xuan-Long Yi; Jiang Li; Dong-Mei Meng; Yan-Jun Liu; Yan-Hong Liu; Hong-Min Ma; Ying Yuan; Shi-Chao Xing
Journal:  Iran J Public Health       Date:  2018-06       Impact factor: 1.429

10.  Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate.

Authors:  Anne Ruiz; Ivan Gautschi; Laurent Schild; Olivier Bonny
Journal:  Front Physiol       Date:  2018-06-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.